SOURCE: BioMedReports


May 18, 2011 09:20 ET

Northwest Biotherapeutics' Partnership Announcement Is Significant in Several Ways

LOS ANGELES, CA--(Marketwire - May 18, 2011) - This morning's announcement that Northwest Biotherapeutics (OTCBB: NWBO) is partnering with Fraunhofer, the largest applied research foundation in Europe is significant in several ways.

As previously reported, NWBO has been quietly positioning itself for some big moves. In recent months, the company has been busy resuming enrollment and adding more locations to their clinical trials for Glioblastoma multiforme ("GBM") brain cancer. In addition, they have been quietly cleaning up corporate debt, and talking to several potential partners about their DCVax® platform technology -- which can be applied to multiple cancers.

It appears today's news may be the first of several developments which may help position the Bethesda, MD-based company well ahead of other emerging cancer immunotherapy players.

A special report on the significance of today's news and what it could mean to investors is available now at:

In addition, investors interested in accessing BioMedReports' new, complete database of clinical trials and upcoming FDA and worldwide regulatory decisions which can be used to make more profitable trades can go to:

News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Full disclosures and information about the stocks are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556